---
title: "GILEAD SCIENCES EUROPE LTD. - Payment Practices"
date: 2026-01-22
url: https://paymentcheck.co.uk/company-search/05510315/gilead-sciences-europe-ltd
description: "View payment practices for GILEAD SCIENCES EUROPE LTD.. Average time to pay: 33 days."
---

# GILEAD SCIENCES EUROPE LTD.

## Company Information

- **Company Number:** 05510315
- **Status:** Active
- **Company Type:** Private limited Company
- **Incorporated:** 15 July 2005
- **Registered Address:** 2 Roundwood Avenue, Stockley Park, Uxbridge, Middlesex, UB11 1AF
- **Industry:** Professional Services
- **Region:** London

## Payment Statistics

- **Average Time to Pay:** 33 days
- **Invoices Paid Within 30 Days:** 60%
- **Invoices Paid Between 31-60 Days:** 33%
- **Invoices Paid Later Than 60 Days:** 7%
- **Invoices Not Paid Within Agreed Terms:** 39%

## Payment Terms

- **Standard Payment Terms:** Payment made on undisputed amounts 30-45 Days after receipt of the invoice. Once an invoice is 
approved it is sent for payment in the next available weekly payment run.
- **Shortest Payment Period:** 30 days
- **Longest Payment Period:** 45 days
- **Maximum Contractual Period:** 45 days

## Payment Practices

- **Payment Terms Changed:** Not available
- **Suppliers Notified of Changes:** Not available
- **E-Invoicing Offered:** True
- **Supply Chain Financing Offered:** False
- **Participates in Payment Codes:** No

## Dispute Resolution

Each engagement with a supplier will be managed by a Gilead business owner. Should a dispute arise 
in relation to payment for such engagement, it will be discussed by the supplier and the relevant 
Gilead business owner as soon as possible and escalated internally with a view to reaching 
resolution.

## Summary

Gilead Sciences Europe Ltd. is a biopharmaceutical company that focuses on developing innovative treatments for life-threatening diseases. They operate in over 35 countries across Europe, Middle East, and Africa.\n\nSustainability is a key focus for Gilead Sciences Europe Ltd. They are committed to reducing their environmental impact and promoting sustainable practices throughout their operations. They have implemented various initiatives such as reducing carbon emissions, promoting energy efficiency, and reducing waste.\n\nThe company's products and services include treatments for HIV, viral hepatitis, and other serious medical conditions. They have a wide portfolio of medicines that are approved for use in Europe, and they continue to invest in research and development to bring new treatments to patients.\n\nThe key people at Gilead Sciences Europe Ltd. include their President, Christina M. Trinchieri, and their Executive Vice President and Chief Financial Officer, Andrew Dickinson. They are supported by a team of experienced leaders in the biopharmaceutical industry.\n\nCustomers and stakeholders can contact Gilead Sciences Europe Ltd. through their website, which provides detailed information about their products, clinical trials, and corporate responsibility efforts. Their registered office address is located in Cambridge, United Kingdom.\n\nIn conclusion, Gilead Sciences Europe Ltd. is a leading biopharmaceutical company with a strong focus on sustainability and developing life-saving treatments. Their commitment to innovation and responsible business practices make them a trusted partner in the healthcare industry.

---

*Data sourced from official UK government payment practices reports. Last updated: 2026-01-22*